Amazon, seen as a pharma threat, may go after medical device and supply sales before it leaps into drugs, a new report suggests.
Launched for lung cancer awareness month in November, the “tALK+” (Talk Positive) campaign focuses on the ALK-positive form of lung cancer.
Will pharma learn to love Twitter now that it’s doubled its character limit to 280?
If recent numbers—and a new doctor survey—are any indication, Tesaro's Zejula has the lead in ovarian cancer. But that could change.
Merck and GSK are coping with hepatitis A vaccine shortages as the U.S. is experiencing deadly outbreaks.
Pharma can usually look back at FDA enforcement letters for insight into the agency's thinking on marketing communications. Not this year.
Back in August, Novartis published findings from the phase 3 Cantos trial of Ilaris that weren't "fully compelling to payers."
The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.
Novartis’ Cosentyx currently leads a crop of immunology meds from a who’s who of Big Pharma. And the company intends to keep it that way.
J&J dropped a lawsuit accusing Samsung Bioepis of infringing patents on Remicade, a $5 billion med that now faces biosimilar rivals.